UNSPSC 51292806: Milnacipran hydrochloride

This classification denotes an antidepressant agent and adrenergic agent with the molecular formula C15H22N2O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier RNZ43O5WW5, chemically known as (z)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanecarboxamide hydrochloride but more generally known as milnacipran hydrochloride, which bears US NIH Compound Identifier 55480. European Medicines Agency schedules Milnacipran hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03297MIG.

UNSPSC 51292806 Milnacipran hydrochloride is a Commodity code that nominally covers a specific pharmaceutical active pharmaceutical ingredient, but recent state and local activity under this code shows little alignment with the code's narrow product scope. The three most recent opportunities posted — a Seminole County naloxone and drug deactivation systems procurement, a Texas HHS therapeutic pharmacy initiative RFI, and a Minnesota multistate cooperative purchasing RFP for generic pharmaceuticals and OTC products — involve naloxone, prescription fulfillment infrastructure, and broad generic pharmaceutical categories rather than milnacipran hydrochloride specifically. The mismatch suggests either tagging error in the source data or use of this code as a catch-all for pharmaceutical procurement across state and local health agencies. When opportunities do appear under the code, they reflect county health departments, state health and human services agencies, and multistate cooperative purchasing alliances seeking to procure finished pharmaceutical products, drug-deactivation systems, and prescription-fulfillment capability rather than raw active pharmaceutical ingredients.

Recent solicitations originate from Florida (Seminole County), Texas (Texas Health and Human Services Commission), and Minnesota (MMCAP, administered by the Minnesota Department of Administration), representing a geographic spread across the Southeast, South, and Upper Midwest. Seminole County posted IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a July 26, 2023, response deadline; the Texas HHS Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for direct-to-manufacturer prescription programs; and MMCAP released RFP S1070000015802 on January 20, 2026, establishing multiple-award contracts for generic pharmaceuticals and OTC products across participating state and local facilities, with a March 26, 2026, proposal deadline and an effective date of July 1, 2026. The code shows no explicit set-aside designations or preferences in the available opportunity records. Given the mismatch between the code's nominal scope and the work actually being solicited, this code does not represent a reliable market segment for vendors seeking pharmaceutical ingredient supply or milnacipran-specific procurement opportunities.